Skip to content
Home » News » Multistate infections linked to EzriCare Artificial Tears prompts CDC investigation

Multistate infections linked to EzriCare Artificial Tears prompts CDC investigation

The Centers for Disease Control and Prevention (CDC) is investigating a multistate cluster of infections linked to the use of EzriCare Artificial Tears, a commonly used brand of eye drops. In light of the investigation, the CDC is urging consumers and health care providers to immediately discontinue the use of the product.

To date, 50 patients in 11 states have been infected with the bacterial infections linked to the use of artificial tears, with some patients suffering permanent vision loss, hospitalization, and even one death. The CDC notes that the infections are often resistant to antibiotics and is conducting a probe and lab tests to determine the cause of the cluster.

Ezricare, the company behind the product, has not received any consumer complaints or reports of adverse reactions related to the investigation. However, in an abundance of caution, the company is advising customers to stop using the product until more information becomes available.


The product was formulated, designed, and imported by Aru Pharma Inc and manufactured by Global Pharma Healthcare PVT LTD. Meanwhile, law firms are already seeking potential claimants in light of the investigation.

As the CDC continues its investigation, it is important for consumers to be aware of the potential dangers associated with the use of artificial tears and to follow the agency’s recommendations to discontinue use until more information becomes available.

Infections of the eye can be serious and can lead to permanent vision loss if not treated promptly. If you have been using EzriCare Artificial Tears and are experiencing any symptoms of eye infections, such as redness, itching, swelling, or discharge, it is important to seek medical attention immediately.

The CDC is working with state and local health departments to determine the cause of the cluster of infections and is urging consumers and health care providers to remain vigilant and to report any adverse reactions or symptoms to the agency. The safety of the public is the top priority, and the CDC will continue to update the public as more information becomes available.

Tags:
Categories: News

Top